[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-haemorrhagic-telangiectasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-haemorrhagic-telangiectasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100624808","non-invasive-detection-of-pulmonary-right-to-left-shunts-using-the-sonas-ultrasound-device-100624808",false,"NCT07414446","Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device","Novel Approach For The Non-Invasive Detection of Pulmonary Right-to-Left Shunts","SONAS","Inclusion Criteria:\n\n* Age 18 years or older.\n* Suspected or confirmed hereditary hemorrhagic telangiectasia (HHT).\n* Incidentally: Patients who have experienced cryptogenic stroke\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Known or suspected fracture(s) of the temporal \u002F parietal skull bones, or with open skin injuries in the anatomical area of the temporal \u002F parietal lobes.\n* Patients with known metal skull implants in the anatomical area of the temporal \u002F parietal bones, or with anatomical formation of the head or ear tha may interfere with proper headset placement.\n* Patients with known allergies or reactions to parabens, which are present in the gel pad material of the applied part.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble echocardiogram (TTCE). The main questions it aims to answer are:\n\n1. How accurately does SONAS detect right-to-left shunts compared to the standard TTCE test?\n2. Can SONAS results help tell the difference between shunts in the heart and shunts in the lungs?\n\nParticipants will wear a headband with the SONAS device on the head while they undergo their routine TTCE bubble test. They will receive the usual contrast (agitated saline) through a vein, and both SONAS and TTCE signals will be recorded at the same time. There will be one examination in rest, and one during a breathing exercise (the Valsalva manoeuvre).",[27,28,29],"Hereditary Haemorrhagic Telangiectasia","PFO - Patent Foramen Ovale","Pulmonary Arteriovenous Malformation",[31,29,32,33,34,35,36,37],"Hereditary Hemorrhagic Telangiectasisa","Right-to-Left Shunt","Contrast Echocardiography","Transcranial Ultrasound","Microbubbles","Patent Foramen Ovale","Cryptogenic Stroke","RECRUITING","2026-02-10",{"date":41,"type":42},"2026-02-17","ACTUAL",{"date":44,"type":42},"2026-01-07",{"date":46,"type":21},"2026-04-01",{"name":48,"class":49},"St. Antonius Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100601523","immunological-effects-of-iron-supplementation-in-hht-disease-100601523","NCT07111598","Immunological Effects of Iron Supplementation in HHT Disease","Fer&RO","Inclusion Criteria:\n\n* For all three groups:\n\n  * Adult patient diagnosed with HHT (meeting 3 or 4 Curaçao criteria).\n  * Documented pathogenic mutation in one of the following genes: ENG, ACVRL1, or MADH4.\n  * Patient enrolled in the CIROCO cohort.\n  * Written informed consent freely given and signed by the patient.\n  * Patient covered by a social security scheme or equivalent.\n  * Routine biological follow-up for HHT performed within the 15 days preceding the inclusion visit (complete blood count, reticulocytes, ferritin, CRP, calcium, phosphorus).\n* Specific to Group 1:\n\n  * Ferritin \\> 25 µg\u002FL\n  * No iron supplementation (oral or intravenous) in the past 3 months\n  * No red blood cell transfusion in the past 3 months\n* Specific to Group 2:\n\n  * Ferritin \\> 25 µg\u002FL\n  * Ongoing oral iron therapy, or at least one intravenous iron infusion, or at least one red blood cell transfusion within the past 3 months\n* Specific to Group 3:\n\n  * Ferritin \\\u003C 25 µg\u002FL\n  * No iron supplementation (oral or intravenous) in the past 3 months\n  * No red blood cell transfusion in the past 3 months\n\nExclusion Criteria:\n\n* Patients with hemoglobin levels \\\u003C 90 g\u002FL.\n* Patients with active cancer or recent cancer remission (\\\u003C 3 months) that may alter the immune profile.\n* Patients with an active infection or recent infection recovery (\\\u003C 3 months) that may alter the immune profile.\n* Patients with an autoimmune or autoinflammatory disease, either active or recently treated (\\\u003C 3 months), requiring immunosuppressive therapy and potentially altering the immune profile.\n* Pregnant, postpartum, or breastfeeding women.\n* Minors.\n* Individuals deprived of liberty by judicial or administrative decision.\n* Individuals undergoing psychiatric care.\n* Individuals admitted to a healthcare or social institution for reasons other than research participation.\n* Adults under legal protection (guardianship, curatorship).\n* Individuals participating in another interventional clinical trial with an exclusion period still in effect at the time of pre-inclusion.","99 Years",{"count":60,"type":21},155,[24],"Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France. Clinical manifestations include recurrent nosebleeds (epistaxis), cutaneous telangiectasias, and visceral arteriovenous malformations (AVMs) that may affect the lungs, gastrointestinal tract, liver, and brain.\n\nBeyond vascular abnormalities, patients often present with a decrease in circulating T lymphocytes (T-cell lymphopenia), which can be profound but remains unexplained. There is also a distinct infectious risk profile associated with the disease: brain abscesses in the presence of pulmonary AVMs (pAVMs), and osteoarticular infections in patients with the longest durations of epistaxis. However, no definitive correlation has been established between T-cell lymphopenia and infection risk.\n\nIron-deficiency anemia is a frequent complication in HHT, affecting about 50% of patients, with a mean age of onset around 36 years. Its prevalence increases with age. These patients typically require prolonged and high-dose iron supplementation, administered either orally or intravenously, which may expose them to side effects not observed in other clinical contexts. In a previous study, we identified a correlation between the level of iron supplementation (none, oral, or intravenous) and the severity of T-cell lymphopenia.\n\nThis association may be explained by two potential mechanisms linking iron metabolism to immune function:\n\n* A direct toxic effect of iron on immune system homeostasis\n* Impaired lymphocyte production resulting from iron deficiency, with the type of supplementation serving as an indirect marker of deficiency severity We propose a prospective study designed to differentiate between these two hypotheses. The aim of the study is to characterize the impact of iron deficiency and iron supplementation on the immune system of patients with HHT.",[27],[65,66,67],"Hereditary haemorrhagic telangiectasia (HHT)","iron supplementation","lymphopenia","2025-09-30",{"date":70,"type":42},"2025-10-03",{"date":72,"type":42},"2025-09-24",{"date":74,"type":21},"2028-12-31",{"name":76,"class":49},"Hospices Civils de Lyon"]